

**PHA5878C Patient Care III:
Introduction to Cardiovascular and Pulmonary Disease
Fall 2020
6 Credit Hours – [A-E Grading]**

This is the third of an eight-course sequence that prepares the student to provide patient-centered care by serving as a collaborative interprofessional team-member who is an authority on pharmacotherapy. This course focuses on providing patient-centered care to patients who have cardiovascular and pulmonary disorders. Learners will develop, integrate, and apply knowledge from the foundational disciplines (i.e., pharmaceutical, social/behavioral/administrative, and clinical sciences) and apply the Pharmacists' Patient Care Process in solving case-based scenarios of patients with cardiovascular and pulmonary diseases.

Teaching Partnership Leader

Katie Vogel Anderson, PharmD, BCACP

Email: kvanderson@cop.ufl.edu

Phone: 352-273-6240

Office Hours: Posted on Canvas

See Appendix A for the Faculty and Staff directory.

Entrustable Professional Activities

This course will prepare students to perform the following activities, which the public entrusts a pharmacist to perform:

1. Collect information to identify a patient's medication-related problems and health-related needs.
 - ST1.4. Use health records to determine a patient's health-related needs relevant to setting of care and purpose of the encounter.

2. Analyze information to determine the effects of medication therapy, identify medication-related problems, and prioritize health-related needs.
 - ST2.3. Interpret laboratory test results
 - ST 2.3b. Interpret data related to personalized medicine.
 - ST2.4. Perform a comprehensive medication review (CMR) for a patient
 - ST2.7. Evaluate an existing drug therapy regimen

3. Establish patient-centered goals and create a care plan for a patient in collaboration with the patient, caregiver(s), and other health professionals that is evidence-based and cost-effective
 - ST3.1. Follow an evidence-based disease management protocol.
 - ST3.2. Develop a treatment plan with a patient. (including recommend therapeutic alternatives and generic substitution)
 - ST3.4. Select monitoring parameters to determine the therapeutic and adverse effects related to the treatment plan.

4. Implement a care plan in collaboration with the patient, caregivers, and other health professionals.
 - ST4.1. Write a note that documents the findings, recommendations, and plan from a patient encounter.
 - ST4.4. Assist a patient with behavior change (e.g., use shared decision making and motivational strategies).

5. Follow-up and monitor a care plan.
 - ST5.3. Recommend modifications or adjustments to an existing medication therapy regimen based on patient response.

6. Collaborate as a member of an interprofessional team.
 - ST6.4. Use setting appropriate communication skills when interacting with others.

7. Identify patients at risk for prevalent diseases in a population.
 - ST7.1. Perform a screening assessment to identify patients at risk for prevalent diseases in a population (e.g., hypertension, diabetes, depression).

9. Maximize the appropriate use of medications in a population.
 - ST9.2. Apply cost-benefit, formulary, and/or epidemiology principles to medication-related decisions.

12. Use evidence-based information to advance patient care.
 - ST12.1. Retrieve and analyze scientific literature to make a patient-specific recommendation.

Course-Level Objectives

Upon completion of this course, the student will be able to:

Given a case of a patient with one or more of the above disorders/pharmacotherapy needs, integrate knowledge and use clinical reasoning skills to accomplish the following steps:

1. **Collect:** Gather subjective and objective information and analyze the data to understand the relevant medical/medication history and clinical status of the patient.
 - a. Subjective and objective information is collected through comprehensive medication review with the patient, medical record review, pharmacy profile review, and communication with other members of the health care team.
 - b. A holistic view is initiated during collection in order to consider physiological, psychological, and sociological variables of the patient and this view is maintained throughout the patient care process.
2. **Assess:** Assess the information collected and formulate a problem list consisting of the patient's active medical problems and medication therapy problems in order to prioritize medication therapy recommendations to achieve the patient's overall health goals.
 - a. Assess the patient's active medical conditions, taking into account clinical and patient goals of therapy.
 - b. Assess the indication, effectiveness, safety, adherence and convenience (administration, access, affordability) of each medication the patient is taking.
 - c. Include in the assessment an evaluation of risk factors, relevant psychosocial issues, and the need for preventative care or for referral to another healthcare practitioner for further evaluation
 - d. Formulate a medication therapy problem list, classifying the patient's medication therapy problems based on indication, effectiveness, safety, and compliance.
 - e. Prioritize the patient's medication therapy problems.
3. **Plan:** Develop an individualized patient-centered care plan in collaboration with other health care professionals and the patient/caregiver that is evidence-based and as affordable as possible.
 - a. For each problem, create patient-centered goal(s) in collaboration with the patient/caregiver and other members of the healthcare team
 - b. Develop a care plan to manage the patient's active medical conditions and resolve the identified medication therapy problems.
 - c. Identify monitoring parameters to assess effectiveness, safety, adherence, and quality of life.
4. **Implement:** Implement the care plan in collaboration with other health care professionals and the patient/caregiver.
 - a. For each condition and associated recommended strategy for resolving identified MTPs, provide the medication order in its entirety, including full drug name, dose, dosage form, route of administration, dosing interval, duration of therapy
 - i. Discuss the care plan with the patient.
 - ii. Educate the patient on his/her medications (which may include explanations of medication action, the regimen or its proper discontinuation, proper medication use and storage, expected results and

when to expect them, possible adverse effects, and when and how to follow-up or seek additional care.

- b. Where appropriate, contribute to coordination of care by providing documentation to other providers using an evidence-based method of communication, such as SBAR (Situation, Background, Assessment, Recommendation) or SOAP (Subjective, Objective, Assessment, Plan)
5. **Follow-up with the Patient:** Monitor and evaluate the effectiveness of the care plan and modify the plan in collaboration with other health care professionals and the patient/caregiver.

Course Pre-requisites

1. Completion of all Year 1 Pharm.D. program coursework including milestones.
2. PHA5781C Patient Care I
3. PHA5782C Patient Care II
4. PHA5755 Principles of Medical Microbiology, Immunology, and Virology

Course Co-requisites

1. PHA5163L Professional Practice Skills Laboratory III

Course Outline and Tentative Schedule

Please routinely check your campus calendar and the Canvas course site for any messages about changes in the schedule including meeting dates/times, deadlines, and room changes.

Date and Time	Activity	Module	Unit Topic	Contact Time	Faculty
10/5/2020	Module	1	Introduction to CV Modules		Rhonda Cooper DeHoff
10/5/2020	Video Lecture	1.1	Introduction to CV Disease and Overview of Module	0.5	Eric A Dietrich
10/5/2020	Video Lecture	1.2	Introduction Review of CV Pathophysiology	0.5	Maureen Keller-Wood
10/5/2020	Video Lecture	1.3	ASCVD Risk Assessment	0.5	Rhonda Cooper-DeHoff
10/5/2020	Module	2	Hypertension		Rhonda Cooper DeHoff
10/5/2020	Video Lecture	2.1	Pathophysiology of Hypertension	1	Maureen Keller-Wood
10/5/2020		2.2	Pharmacology: Autonomic Function, Sympathetic System Drug Classes: Beta Blockers and Calcium Channel Blockers		Charles Jason Frazier
10/5/2020	Video Lecture	2.2.1	Calcium Channel Blockers - Introduction	0.5	Charles Jason Frazier
10/5/2020	Video Lecture	2.2.2	Calcium Channel Blockers - MOA	0.5	Charles Jason Frazier
10/5/2020	Video Lecture	2.2.3	Calcium Channel Blockers - Specifics	0.5	Charles Jason Frazier
10/5/2020	Video Lecture	2.2.4	Beta Blockers - Introduction and MOA	0.5	Charles Jason Frazier
10/5/2020	Video Lecture	2.2.5	Beta Blockers - Specifics	0.5	Charles Jason Frazier

10/5/2020		2.3	Pharmacology: Renin Angiotensin System and volume Drug Classes: ACE inhibitors, ARBs, thiazide diuretics		Eric Krause
10/6/2020	Video Lecture	2.3.1	Targeting the RAAS to Alleviate Hypertension	0.75	Eric Krause
10/6/2020	Video Lecture	2.3.2	Diuretics and Hypertension: Interactions with ACEi and ARB	0.9	Eric Krause
10/6/2020		2.4	Medicinal Chemistry--Drug Classes: beta blockers, calcium channel blockers, ACE inhibitors, ARBS, thiazide diuretics		Jane V Aldrich
10/6/2020	Video Lecture	2.4.1	Medicinal Chemistry of beta blockers	0.5	Jane V Aldrich
10/6/2020	Video Lecture	2.4.2	Medicinal Chemistry of the renin-angiotensin system	0.5	Jane V Aldrich
10/6/2020	Video Lecture	2.4.3	Medicinal Chemistry of calcium channel blockers	0.5	Jane V Aldrich
10/6/2020	Video Lecture	2.4.4	Medicinal Chemistry of diuretics and other drugs for hypertension	0.25	Jane V Aldrich
10/7/2020		2.5	Pharmacotherapy and Management of Hypertension		Rhonda Cooper-DeHoff
10/7/2020	Video Lecture	2.5.1	Pharmacotherapy and Management of Hypertension Part 1	0.67	Rhonda Cooper-DeHoff
10/7/2020	Video Lecture	2.5.2	Pharmacotherapy and Management of Hypertension Part 2	0.67	Rhonda Cooper-DeHoff
10/7/2020	Video Lecture	2.5.3	Pharmacotherapy and Management of Hypertension Part 3	0.66	Rhonda Cooper-DeHoff
10/7/20 @1:55-3:50pm	Active Learning Session-Zoom	1.1-2.4	Q&A Discussion: Hypertension	1	Charles Jason Frazier, Eric Krause, Jane V Aldrich,

					Maureen Keller-Wood
10/8/2020		2.6	Transcending Concept - Social: Fighting Obesity; Health Disparities; Hypertension		Rhonda Cooper-DeHoff
10/8/2020	Reading	2.6	Cardiovascular Health in African Americans A Scientific Statement From the American Heart Association Endorsed by the American College of Cardiology Circulation. 2017;136:00–00. DOI: 10.1161/CIR.0000000000000534 Highlighted sections only!	0.5	Rhonda Cooper-DeHoff
10/8/2020	Video Other	2.6	The Weight of the Nation: Poverty and Obesity (24:05) https://www.youtube.com/watch?v=7MJnm5X9NN0	0.5	Rhonda Cooper-DeHoff
10/8/2020		2.7	Transcending Concept - Health & Wellness: Hypertension		Katherine L Vogel Anderson
10/8/2020	Reading	2.7	How Can I Make My Lifestyle Healthier? (PDF)	0.1	Katherine L Vogel Anderson
10/8/2020	Video Lecture	2.7	Promoting Health and Wellness for Cardiovascular Health	0.5	Katherine L Vogel Anderson
10/9/20 @10:40-12:35pm	Active Learning Session--Hybrid	2.5-2.7	ALS 1 Part 1: Hypertension	1	Charles Jason Frazier, Eric Krause, Jane V Aldrich, Katherine L Vogel Anderson,

					Maureen Keller-Wood, Rhonda Cooper-DeHoff
10/12/20 @10:40-12:35pm	Active Learning Session--Hybrid	2.5-2.7	ALS 1 Part 2: Hypertension	1	Charles Jason Frazier, Eric Krause, Jane V Aldrich, Katherine L Vogel Anderson, Maureen Keller-Wood, Rhonda Cooper-DeHoff
	Module	3	Dyslipidemia		Eric A Dietrich
10/12/2020	Video Lecture	3.1	Lipid Metabolism	0.5	Andrew Tenpas
10/12/2020	Video Other	3.1	Physiology of Lipoproteins Cholesterol https://www.youtube.com/watch?v=PkkH8ITxvzA	0.25	Eric A Dietrich
10/12/2020	Video Lecture	3.2	Pharmacology of Antihyperlipidemics	0.75	Angelina Vascimini
10/12/2020	Reading	3.2	Table 21-11 in Chapter 21 Dyslipidemia in Pharmacotherapy: A Pathophysiologic Approach, 10e Eds. Joseph T. DiPiro, et al. New York, NY: McGraw-Hill, , http://accesspharmacy.mhmedical.com/content.aspx?bookid=1861&sectionid=146057587 .	0.25	Angelina Vascimini

10/12/2020	Video Lecture	3.3.1	Medicinal Chemistry of Antihyperlipidemics Part 1	0.5	Guangrong Zheng
10/12/2020	Video Lecture	3.3.2	Medicinal Chemistry of Antihyperlipidemics Part 2	0.5	Guangrong Zheng
10/13/2020	Video Lecture	3.4	Treatment of Dyslipidemia	1.5	Eric A Dietrich
10/13/2020	Video Lecture	3.5	Transcending Concept - Informatics: HIT Supporting Outpatient Drug Use	0.5	Khoa Nguyen
10/13/2020	Video Lecture	3.6	Transcending Concept - Interprofessional Communications & Collaboration: Shared Decision Making	0.5	Eric A Dietrich
10/14/2020	Module	4	Ischemic Heart Disease		Julio Duarte
10/14/2020	Video Lecture	4.1	Pathophysiology of Ischemic Heart Disease	0.5	Maureen Keller-Wood
10/14/2020	Video Lecture	4.2	Pharmacology and Medicinal Chemistry of Nitrodilators	0.75	Lina Cui
10/15/20 @10:40-12:35pm	Active Learning Session--Hybrid	3	ALS 2 Part 1: Hyperlipidemia	1	Eric A Dietrich, Guangrong Zheng
10/15/2020	Video Lecture	4.3	Management of Ischemic Heart Disease	1	Julio Duarte
10/15/2020	Video Lecture	4.4	Transcending Concept - Personalized Medicine: Cardiovascular Diseases	0.5	Larisa Humma Cavallari
10/15/2020		4.5	Transcending Concept - Evidence-based Practice: Cardiovascular Clinical Trials		Julio Duarte
10/15/2020	Reading	4.5.1	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med 2018;379:1509-18.	0.5	Julio Duarte
10/15/2020	Video Lecture	4.5.2	Cardiovascular Clinical Trials	0.5	Julio Duarte

10/16/20 @10:40-12:35pm	Active Learning Session-Hybrid	3	ALS 2 Part 2: Hyperlipidemia	1	Eric A Dietrich, Guangrong Zheng
Due at 12:35PM on 10/16/20	Graded Assignment	3	Written Assignment 1		Eric A Dietrich
10/19/20 @ 10:40-12:35pm	Active Learning Session--Hybrid	4	ALS 3 Part 1: Ischemic Heart Disease	1	Julio Duarte, Larisa Humma Cavallari, Lina Cui, Maureen Keller-Wood
10/19/20 @ 1:55-3:50pm	Active Learning Session--Zoom	4	ALS 3 Part 2: Ischemic Heart Disease	1	Julio Duarte, Larisa Humma Cavallari, Lina Cui, Maureen Keller-Wood
	Module	5	Anticoagulation and Acute Coronary Syndrome		Stacy Alan Voils
10/20/2020		5.1	Pathophysiology of Blood Clotting		Katherine L Vogel Anderson

10/20/2020	Reading	5.1.1	Chapter 37: "Venous Thromboembolism." in Pharmacotherapy: A Pathophysiologic Approach, 11e Eds. Joseph T. DiPiro, et al. New York, NY: McGraw-Hill, , http://accesspharmacy.mhmedical.com/content.aspx?bookid=2577&sectionid=219316417 .	0.3	Katherine L Vogel Anderson
10/20/2020	Reading	5.1.2	Plaque Rupture and Clot Formation	0.1	Katherine L Vogel Anderson
10/20/2020	Video Lecture	5.1.3	Pathophysiology of Blood Clotting	0.5	Katherine L Vogel Anderson
10/20/2020	Video Lecture	5.2	Pharmacology of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy	1.5	Stacy Alan Voils
10/21/20 8:30 1030am	Exam	1 4	Exam 1	2.5	
10/22/2020	Video Lecture	5.3	Medicinal Chemistry of Anticoagulants, Fibrinolytic Agents, and Antiplatelet Therapy	1	Lina Cui
10/22/2020		5.4	Management of Acute Coronary Syndrome		Katherine L Vogel Anderson
10/22/2020	Reading	5.4.1	ACS Table Charts		Katherine L Vogel Anderson
10/22/2020	Video Lecture	5.4.2	Management of Acute Coronary Syndrome	0.75	Katherine L Vogel Anderson
	Module	6	Heart Failure		Larisa Humma Cavallari
10/22/2020	Video Lecture	6.1.1	Pathophysiology of Heart Failure Part 1	0.75	Maureen Keller-Wood

10/22/2020	Video Lecture	6.2	Pharmacology of Inotropic Agents, Glycosides, Nephilysin Inhibitors, Aldosterone Antagonists		Maureen Keller-Wood
10/22/2020	Video Lecture	6.2	Pharmacology of Treatment of Heart Failure	0.5	Maureen Keller-Wood
10/23/20 @ 1:55-3:50pm	Active Learning Session--Zoom	5	ALS 4 Part 1: ACS	1	Katherine L Vogel Anderson, Lina Cui, Stacy Alan Voils
10/26/20 @8:30-10:25am	Active Learning Session--Zoom	5	ALS 4 Part 2: ACS	1	Katherine L Vogel Anderson, Lina Cui, Stacy Alan Voils
10/26/2020	Video Lecture	6.3	Medicinal Chemistry of Inotropic Agents, Glycosides, Aldosterone Antagonists	1.25	Lina Cui
10/26/2020		6.4	Management of Chronic Heart Failure (HF _r EF & HF _p EF)		Larisa Humma Cavallari
10/26/2020	Video Lecture	6.4.1	Management of Chronic Heart Failure Part 1	0.75	Larisa Humma Cavallari
10/26/2020	Video Lecture	6.4.2	Management of Chronic Heart Failure Part 2	0.75	Larisa Humma Cavallari
10/27/2020	TBD	6.5	Transcending Concept - Patient Safety/Med Errors; Root Cause Analysis: Medication Reconciliation		Kimberly Atkinson

10/28/20 @8:30am – 10:25am	Active Learning Session-- Zoom	6.1-6.2	ALS 5: Pathophysiology of Heart Failure	1	Maureen Keller-Wood
10/28/2020	Module	7	Anticoagulation & Arrhythmias		Katherine L Vogel Anderson
10/28/2020	Video Lecture	7.1	Individualized Heparin and Warfarin Dosing	1	Katherine L Vogel Anderson
10/28/2020	Video Lecture	7.2.1	Venous Thromboembolism (VTE)	1	Katherine L Vogel Anderson
10/28/2020	Video Lecture	7.3	Personalized Medicine CV: Warfarin Pharmacogenetics	1	Larisa Humma Cavallari
10/28/2020	Video Lecture	7.4.1	Pathophysiology of Arrhythmias Part 1	0.75	Maureen Keller-Wood
10/28/2020	Video Lecture	7.4.2	Pathophysiology of Arrhythmias Part 2	0.5	Maureen Keller-Wood
10/29/20 @10:40- 12:35pm	Active Learning Session-- Hybrid	6.3-6.5	ALS 6 Part 1: Heart Failure	1	Larisa Humma Cavallari, Lina Cui, Maureen Keller-Wood, Kim Atkinson
10/29/2020	Video Lecture	7.5	Introduction to Electrocardiology	0.5	Katherine L Vogel Anderson
10/29/2020	Reading	7.5	DiPiro Chapter - ECG section ONLY; link on Canvas		Katherine L Vogel Anderson
10/29/2020	Video Lecture	7.6	Pharmacology of Antiarrhythmics	0.5	Katherine L Vogel Anderson

10/30/20 @ 140-12:35pm	Active Learning Session--Hybrid	6.3-6.5	ALS 6 Part 2: Heart Failure	1	Larisa Humma Cavallari, Lina Cui, Maureen Keller-Wood, Kim Atkinson
10/30/2020	Video Lecture	7.7	Medicinal Chemistry of Antiarrhythmics	1	Lina Cui
10/30/2020	Video Lecture	7.8	Management of Arrhythmias	1	Katherine L Vogel Anderson
10/30/2020	Video Lecture	7.9	Pharmacokinetics of Digoxin and Antiarrhythmics	0.5	Mike Ujhelyi
11/2/20 @10:40-12:35pm	Active Learning Session--Zoom	7	Discussion Q&A: Anticoagulation & Arrhythmias	1	Katherine L Vogel Anderson, Maureen Keller-Wood
11/2/2020	Module	8	Asthma		Michelle Farland
11/2/2020	Video Lecture	8.1	Asthma Pathophysiology, Clinical Presentation, Diagnosis	0.5	Michelle Farland
11/2/2020	Video Lecture	8.2	Pharmacology of Oral and Inhaled Corticosteroids, Short-acting Beta-agonists, Long-acting Beta-agonists, Muscarinic Agents	1.25	Guenther Hochhaus
11/2/2020		8.3	Medicinal Chemistry of Oral and Inhaled Corticosteroids, Short-acting Beta-agonists, Long-acting Beta-agonists, Muscarinic Agents		Jane V Aldrich
11/2/2020	Video Lecture	8.3.1	Medicinal Chemistry of Beta Agonists	0.5	Jane V Aldrich
11/2/2020	Video Lecture	8.3.2	Medicinal Chemistry of Corticosteroids	0.5	Jane V Aldrich
11/2/2020	Video Lecture	8.3.3	Medicinal Chemistry of Antimuscarinics and Other Drugs for Asthma and COPD	0.5	Jane V Aldrich

11/2/2020	Video Lecture		Monoclonal Antibodies	0.25	Jane V Aldrich
11/3/2020	Video Lecture	8.4	Asthma Management	1.25	Michelle Farland
11/3/2020	Video Other	8.4	Resource link to the wheezing sound found in lecture http://www.easyauscultation.com/cases-waveform?coursecaseorder=4&courseid=201		Michelle Farland
11/3/2020	Reading	8.4	Resource link to an Asthma Action Plan http://www.nhlbi.nih.gov/files/docs/public/lung/asthma_actplan.pdf		Michelle Farland
11/3/2020		8.5	Transcending Concepts - Personalized Medicine: Asthma and Inhalation dosage forms		
11/3/2020	Video Lecture	8.5.1	Personalized Medicine – Asthma	0.5	Caitrin McDonough
11/3/2020	Video Lecture	8.5.2	Transcending Concept – Inhalation dosage forms	0.5	Cary Mobley
11/4/20 @10:40-12:35pm	Active Learning Session-Zoom	7	ALS 7 Part 1: Atrial Fibrillation	1	Katherine L Vogel Anderson, Larisa Humma Cavallari, Lina Cui, Maureen Keller-Wood, Mike Ujhelyi
	Module	9	COPD		Michelle Farland
11/4/2020	Video Lecture	9.1	COPD Pathophysiology, Clinical Presentation, Diagnosis	0.5	Michelle Farland
11/4/2020	Video Lecture	9.2	COPD Management	1	Michelle Farland

11/4/2020	Video Lecture	9.3	Transcending Concepts: Health-Wellness – Smoking Cessation	1	Christina DeRemer
11/4/2020		9.4	Transcending Concept - Communications - Patients: Motivational Interviewing		Teresa Roane
11/4/2020	Video Lecture	9.4.1	Introduction to ComMIt eLearning Modules	0.15	Teresa Roane
11/4/2020	Video Other	9.4.2	ComMIt Module 3: Sense-Making and Practical Reasoning	0.75	Teresa Roane
11/5/20 @10:40-12:35pm	Active Learning Session-Zoom	7	ALS 7 Part 2: Atrial Fibrillation	1	Katherine L Vogel Anderson, Larisa Humma Cavallari, Lina Cui, Maureen Keller-Wood, Mike Ujhelyi
11/5/2020		9.5	Transcending Concept - Population-based Care & Pharmacoeconomics		Hui Shao
11/5/2020	Reading	9.5.1	Impact of COPD Exacerbation Frequency on Costs for a Managed Care Population (PDF)	0.5	Hui Shao
11/5/2020	Video Lecture	9.5.2	Population-Based Care & Pharmacoeconomics in COPD Drug Evaluation	0.5	Hui Shao
11/5/2020	Video Lecture	9.6	Transcending Concept - Specialized Populations: Geriatric Drug Dosing	0.5	Shannon A Miller
11/5/2020		9.7	Transcending Concept - Evidence-Based Practice: Cohort Studies and Confounding and Bias		Yu-Jung (Jenny) Wei

11/5/2020	Reading	9.7.1	A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD (PDF) (Sections to read: Abstract, Article Summary, Methods, Tables 1, 2, and 3 (focusing on results of any death, angina, myocardial infarction and stroke) and Discussion, paragraph 9.) https://ufl.instructure.com/courses/341742/files/33749693/download?wrap=1	0.5	Yu-Jung (Jenny) Wei
11/5/2020	Video Lecture	9.7.2	Transcending Concept: Evidence-Based Practice— Cohort Studies and Confounding & Bias	0.5	Yu-Jung (Jenny) Wei
11/6/20 @ 10:30-12:30pm	Exam	5-7	Exam 2	2.5	
11/9/20 @ 10:40-12:35pm	Active Learning Session-- Zoom	8	ALS 8 Part 1: Asthma	1	Guenther Hochhaus, Jane V Aldrich, Michelle Farland
Due at 12:35pm on 11/9/20	Graded Assign – ment	8	Individual Assignment: Asthma Action Plan		Michelle Farland

11/9/2020	Module	10	Respiratory Conditions		John Allen
11/9/2020	Video Lecture	10.1	Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia	1	John Allen
11/9/2020	Video Lecture	10.2	Transcending Concept - Self-Care: Cough & Cold		Colleen Courey
11/10/2020		10.3	Transcending Concept - Interprofessional Communication: Listen actively, and encourage ideas and opinions of other interprofessional team members.		Carol Anne Motycka
11/10/2020	Video Lecture	10.3.1	Transcending Concept: Interprofessional Communication - Listen actively, and encourage ideas and opinions of other interprofessional team members	0.75	Carol Anne Motycka
11/10/2020	Video Other	10.3.2	Slide 3 - https://youtu.be/Hgug-ShbqDs		Carol Anne Motycka
11/10/2020	Video Other	10.3.3	Slide 15 - https://youtu.be/zDOARcgH_Ew		Carol Anne Motycka
11/10/2020	Video Other	10.3.4	Slide 16 - https://youtu.be/dt3j_LXB76M		Carol Anne Motycka
11/10/2020	Video Other	10.3.5	Slide 18 - https://youtu.be/BXUYalA1nmU		Carol Anne Motycka
11/10/2020	Video Other	10.3.6	Slide 41 - https://youtu.be/4VFPfgbk0z8		Carol Anne Motycka
11/10/2020	Video Lecture	10.4	Lung Cancer	1	David DeRemer

11/12/20@ 10:40- 12:35pm	Active Learning Session-- Zoom	8	ALS 8 Part 2: Asthma	1	Caitrin McDonough , Guenther Hochhaus, Jane V Aldrich, Michelle Farland
11/13/20 @10:40-12:35pm	Active Learning Session-- Hybrid	9	ALS 9 Part 1: COPD	1	Christina DeRemer, Michelle Farland, Shannon A Miller, Teresa Elaine Roane, Yu-Jung (Jenny) Wei
11/16/20 @10:40-12:35pm	Active Learning Session-- Hybrid	9	ALS 9 Part 2: COPD	1	Christina DeRemer, Michelle Farland, Shannon A Miller, Teresa Elaine Roane, Yu-Jung (Jenny) Wei
11/19/20 @10:40-12:35pm	Active Learning Session- Zoom	10	ALS 10 Part 1: Respiratory Conditions Part 1	1	Carol Anne Motycka, David DeRemer, John Allen, Teresa Elaine Roane
11/19/20 @1:55-3:50pm	Active Learning Session-- Zoom	10	ALS 10 Part 2: Respiratory Conditions	1	Carol Anne Motycka, David DeRemer, John Allen, Teresa Elaine Roane

11/20/20 @8:30- 12:35pm	Active Learning Session-- Zoom	1-10	PC 3 Capstone	2	Michelle Farland
Due at 12:35pm on 11/20/20	Graded Assignment	1-10	Capstone Assignment Submission		Michelle Farland
11/23/20 @ 2:00-4:00pm	Exam	1-10	Exam 3: All Modules (2.5hr)		Katherine L Vogel Anderson

Total Contact Hours: 83

Required Textbooks/Readings

1. Dipiro, J, Talbert R, Yee G, Matzke G, Wells B, Posey L. Pharmacotherapy – A pathophysiologic approach. McGraw-Hill Professional, New York, NY, 10th Edition, 2017. ISBN 978-1-259-58748-1
 - Previously used for PHA5782C
 - Available via HSC Library – Access Pharmacy
2. Dipiro, J, Talbert R, Yee G, Matzke G, Wells B, Posey L. Pharmacotherapy – A pathophysiologic approach. McGraw-Hill Professional, New York, NY, 11th Edition, 2020.
 - Previously used for PHA5782C
 - Available via HSC Library – Access Pharmacy
3. Other required readings will be posted in Canvas.

Use [UF VPN to access UF Libraries Resources](#) when off-campus.

The UF HSC library staff can assist you with questions or issues related to accessing online library materials. For assistance contact your College of Pharmacy librarian or visit the [HSC Library Website](#) at this URL: <http://www.library.health.ufl.edu/>

Suggested Textbooks/Readings

Foye WO, Lemke T, Williams DA. Foye's Principles of Medicinal Chemistry, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, PA, 7th Edition, 2013. ISBN-13:978-1609133450; ISBN-10:1609133455

- Previously purchased for PHA5782C
- Not Available via HSC Library

Other Required Learning Resources

EHR Go

EHR Go is an educational EHR used throughout the PharmD curriculum, including in skills lab, patient care courses and capstones. Students will be expected to purchase a subscription to this program.

- Create your EHR Go account by going to: <http://ehrgo.com>.
- Select Subscribe in the upper, right corner and enter the following Pharmacy Student Program Key: S96Y29
- Follow the on-screen instructions to create your account and apply your subscription. Refer to Canvas for more detailed information
 - 2PDs are encouraged to purchase a 2 year Student Subscription
 - 3PDs are encouraged to purchase an Academic Year Student Subscription

Materials & Supplies Fees

None

Student Evaluation & Grading

Evaluation Methods and How Grades are calculated.

[The Canvas© gradebook will be set-up using the percentages below to compute the grade.]

Table 1.1 Evaluation and Grading Above

Assessment Item	Grade Percentage
iRATs [10]	10%
ALS Assignment 1	2%
ALS Assignment 2	2%
Capstone Assignment	4%
Exam 1	24%
Exam 2	24%
Exam 3	34%
Total	100%

Table 1.2 grading scale

Percentage	Letter Grade
92.50-100%	A
89.50-92.49%	A-
86.50-89.49%	B+
82.50-86.49%	B
79.50-82.49%	B-
76.50-79.49%	C+
72.50-76.49%	C

69.50-72.49%	C-
66.50-69.49%	D+
62.50-66.49%	D
59.50-62.49%	D-
< 59.50%	E

Rounding of grades:

Final grades in Canvas will be rounded to the 2nd decimal place. If the decimal is X.495 or higher, Canvas will round the grade to X.50. The above scale depicts this policy and grades are determined accordingly. Grade assignment is made using this policy and NO EXCEPTIONS will be made in situations where a student's grade is "close."

Makeup Assignments

Makeup assignments may be required for excused absences from all Active Learning Sessions. Students will be required to complete the makeup assignment within one week of the missed session.

Educational Technology Use

The following technology below will be used during the course and the student must have the appropriate technology and software.

1. ExamSoft™ Testing Platform
2. Canvas™ Learning Management System

For technical support, navigate to [Educational Technology and IT Support Contact Information](#) at this URL: <http://curriculum.pharmacy.ufl.edu/current-students/technical-help/>

Pharm.D. Course Policies

The Policies in the following link apply to this course. Review the General [Pharm.D. Course Policies](#) carefully, at this URL: <http://curriculum.pharmacy.ufl.edu/current-students/course-policies/>

Course Evaluation Process

Students are expected to provide professional and respectful feedback on the quality of instruction in this course by completing course evaluations online via GatorEvals. Guidance on how to give feedback in a professional and respectful manner is available at <https://gatorevals.aa.ufl.edu/students/>. Students will be notified when the evaluation period opens, and can complete evaluations through the email they receive from GatorEvals, in their Canvas course menu under GatorEvals, or via <https://ufl.bluera.com/ufl/>. Summaries of course evaluation results are available to students at <https://gatorevals.aa.ufl.edu/public-results/>.

Land Acknowledgement

A Land Acknowledgement is a formal statement that recognizes and respects Indigenous Peoples as traditional stewards of this land and the enduring relationship that exists between Indigenous Peoples and their traditional territories. The University of Florida resides on the land

of the Timucua people and Seminole Tribe of Florida. Additionally, we acknowledge that Indigenous land was expropriated from over 120+ tribal nations as part of the Morrill Act, in order to establish the University of Florida. Land acknowledgements do not exist in a past tense or historical context. For more information, visit: <http://www.lspirg.org/knowtheland>.

Appendix A. Faculty and Staff Directory

Teaching Partnership Leader/Course Director:

Katie Vogel Anderson, PharmD, BCACP

Email: kvanderson@cop.ufl.edu

Phone: 352-273-6240

Office Hours: See Canvas

Questions to Ask:

- Concerns about performance
- Guidance when there are performance problems (failing grades)
- General questions about content

Teaching Partnership Faculty Members:

Jane Aldrich, Ph.D.

Email: jaldrich@cop.ufl.edu

Phone: 352-273-8708

John M. Allen, Pharm.D., BCPS, BCCCP, FCCM

Email: john.allen@cop.ufl.edu

Phone: 407-313-7006

Larisa Cavallari, Pharm.D.

Email: lcavallari@cop.ufl.edu

Phone: 352-273-8245

Lina Cui, Ph.D.

Email: linacui@cop.ufl.edu

Rhonda Cooper-DeHoff, Pharm.D., M.S. FAHA, FACC

Email: dehoff@cop.ufl.edu

Phone: 352-273-6184

Christina E. DeRemer, Pharm.D., BCPS, FASHP

Email: cderemer@ufl.edu

Phone: 352-273-6224

David DeRemer, Pharm.D., BCOP, FCCP

Email: dderemer@cop.ufl.edu

Phone: 352-294-8891

Eric Dietrich, PharmD, BCPS

Email: ead1129@ufl.edu

Phone: 352-294-5648

Julio Duarte, Pharm.D., Ph.D.

Email: juliod@cop.ufl.edu

Phone: 352-273-8132

Michelle Farland, Pharm.D., BCPS, CDE

Email: mfarland@cop.ufl.edu

Phone: 352-273-6293

Charles Frazier, Ph.D.

Email: frazier@cop.ufl.edu

Phone: 352-273-7686

Guenther Hocchaus, Ph.D.

Email: hocchaus@cop.ufl.edu

Phone: 352-273-7861

Maureen Keller-Wood, Ph.D.
Email: kellerwd@cop.ufl.edu
Phone: 352-273-7687

Eric Krause, Ph.D.
Email: ekrause@cop.ufl.edu
Phone: 352-273-6977

Caitrin McDonough, Ph.D.
Email: cmcdonough@cop.ufl.edu
Phone: 352-273-6435

Shannon Miller, Pharm.D., BCACP
Email: smiller@cop.ufl.edu
Phone: 407-313-7031

Carol Motycka, Pharm.D., BCACP
Email: motycka@cop.ufl.edu

Khoa Nguyen, PharmD
Email: nguyen.khoa@cop.ufl.edu

Teresa Roane, PharmD
Email: troane@cop.ufl.edu

Hui Shao, MD, PhD
Email: hui.shao@ufl.edu

Mike Ujhelyi, PharmD, FCCP
Email: michael.ujhelyi@ufl.edu

Stacy Voils, PharmD
Email: svoils@cop.ufl.edu

Jenny Wei, PhD
Email: jenny.wei@cop.ufl.edu

Guangrong Zheng, PhD
Email: zhengg@cop.ufl.edu

Instructional Designer:

Julie Thomas, MEd

Email: julie.thomas@ufl.edu

Phone: 352-273-6284

Academic Coordinator:

Name: Misti Merrill

Email: mmerrill@cop.ufl.edu

Office: HPNP 4312, Gainesville Campus

Phone: 352-294-5617

Absence/Tardy Email: absent2pd@cop.ufl.edu (Visit the [course policy site](#) for instructions)

Educational Coordinators

Name: McKenzie Wallen

Email: mwallen@cop.ufl.edu

Office: Jacksonville Campus

Name: Iverta Allen

Email: iallen1@cop.ufl.edu

Office: Orlando Campus

Questions to Ask:

- Issues related to course policies (absences, make up exams, missed attendance)
- Absence/tardy requests (Only the Academic Coordinator handles absence requests)
- Dates, deadlines, meeting places; course materials and directions for assignments
- Questions about grade entries in gradebook (missing grades, incorrect grade)
- Assistance with ExamSoft®. Students may contact the Educational Coordinator for use of Exemplify and assistance during exams. The Academic Coordinator is the contact person for issues related to grading and posting of ExamSoft grades.